CA
NZ
UK
AU
IND
US
● An NYSE minimum-price compliance deadline looms this fall, adding listing pressure to the stock.
● Quantum-Si Incorporated reported second-quarter 2026 results on August 13 that beat thinWall StreetRevenueestimates.
● Skye Bioscience discontinued its Phase 2a CBeyond trial of nimacimab in obesity on August 14, 2026.
● Outlook Therapeutics won FDA approval for LYTENAVA (bevacizumab-vikg) on July 24, 2026, the first and only FDA-approved ophthalmic formulation of bevacizumab.
● OSR Health faces an August 31, 2026 deadline to maintain a $1.00 closing bid price for 10 consecutiveBusinessdays underNasdaqrules.
● Mereo BioPharma Group's American Depositary Shares climbed sharply following its August 11, 2026 second-quarterEarningsrelease.
● Lead candidate laromestrocel, formerly known as Lomecel-B, is an allogeneic, bone-marrow-derived mesenchymal stem cell product being tested in two very different populations.
● Gossamer Bio's stock has crashed 95% this year, trading as aPenny Stockafter a Phase 3 trial miss earlier in 2026.
● DocGo shares have ticked modestly higher over the past month, moving off record lows even as the stock remains under pressure.
● Barinthus Biotherapeutics is nearing aMergerexit, a significant corporate transition for the clinical-stage immunotherapy developer.
Please wait processing your request...